{"id":"NCT00117286","sponsor":"Ferring Pharmaceuticals","briefTitle":"Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","officialTitle":"An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-03","primaryCompletion":"2009-09","completion":"2009-11","firstPosted":"2005-07-06","resultsPosted":"2010-10-21","lastUpdate":"2010-10-21"},"enrollment":57,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":["Degarelix acetate, FE200486"]}],"arms":[{"label":"Degarelix (60 mg to 160 mg)","type":"EXPERIMENTAL"},{"label":"Degarelix (80 mg to 160 mg)","type":"EXPERIMENTAL"}],"summary":"This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.\n\nThe study was terminated when all ongoing participants had been treated for at least 5 years.","primaryOutcome":{"measure":"Participants With Markedly Abnormal Change in Vital Signs and Body Weight","timeFrame":"5 years","effectByArm":[{"arm":"Degarelix (60 mg to 160 mg)","deltaMin":9,"sd":null},{"arm":"Degarelix (80 mg to 160 mg)","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":22,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":30},"commonTop":["Hot flush","Fatigue","Injection site pain","Injection site nodule","Nasopharyngitis"]}}